Inhibikase Therapeutics is no longer a Parkinson's company. After pausing risvodetinib and licensing the neurology franchise to ABLi Therapeutics, the equity is a single late-stage bet that a once-daily imatinib prodrug can finish what generic Gleevec started in pulmonary arterial hypertension without repeating the gut-toxicity dropout that killed the original IMPRES commercial path. The market is pricing a funded registrational story after the RA Capital ATM print and orphan designation, not a proven remodeling drug. The debate is whether IMPROVE-PAH is a smarter second look at a validated anti-proliferative mechanism or a capital-consuming rerun of a known efficacy signal that patients could not stay on.
The strategic reset is complete on paper. Management sold the neurology option for a token upfront, kept a back-end of milestones and double-digit royalties, and bought CorHepta to staff a cardiopulmonary team around IKT-001. A Type C interaction with the Food and Drug Administration let the company skip a standalone mid-stage PAH study and jump into a two-part adaptive registrational design. Conference data in Orlando argued the prodrug stays intact in the gut and converts only in blood, cutting c-Kit inhibition sharply versus imatinib mesylate. That is the entire product claim: same active moiety, better stomach.
Cash at mid-year sat at $159M before the July ATM added $50M of gross proceeds from RA Capital. Research spend more than doubled versus the year-ago quarter as sites opened. The loss widened even as per-share loss stayed flat because the share count roughly doubled. Runway to Part B topline is not a clean cash story. It is conditioned on Series A and Series B warrants exercising on time.
The strongest counterargument is that imatinib already showed hemodynamic benefit in PAH and still failed as a product because patients stopped taking it. Orphan status attaches to the imatinib moiety, not to a unique formulation fortress, so exclusivity is thinner than a new molecular entity story implies. Manufacturing still sits with a WuXi AppTec subsidiary while BIOSECURE politics thicken. Enrollment is early: dozens of sites are live against a planned global footprint near 200. The variables that resolve the equity are Part A pulmonary vascular resistance, whether the warrant stack actually funds the second half of the trial, and whether gut tolerability in sick PAH patients matches the healthy-volunteer poster.